How can a medical device reduce the risk of suffering a stroke?
The Danish start-up Cortrium has developed a sensor for monitoring cardiac arrhythmia. A critical pillar in the early detection of atrial fibrillation. Our sales force presents the medical device to physicians and explains its added value.
Based in Copenhagen, the start-up Cortrium offers a wearable sensor for the early detection of cardiac arrythmia. The collaboration between Pfizer and Cortrium has been in existence since 2016. Since then the two partners have been investigating the suitability of digital solutions to meaningfully complement existing products and therapies for the prevention of cardiovascular disorders. The developed sensor records a longterm-ECG that the doctor can subsequently evaluate. Wireless by design, the sensor adds additional value to patients due to the convenience and ease of its use.
This innovative technology developed by Cortrium helps physicians and patients to diagnose conditions such as atrial fibrillation at an early stage, consequently reducing the risk of suffering a stroke. Since the spring of 2018, the start-up has been granted access to some of Pfizer’s sales channels. This entails that the specially trained field force from Pfizer presents the medical device to physicians and explains its added value.